Trials / Not Yet Recruiting
Not Yet RecruitingNCT06866600
IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure
Study on the Safety and Efficacy of Human IPSC-Derived Cardiomyocytes in the Treatment of End-Stage Heart Failure
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- HELP Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 35 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial investigates the safety, feasibility, and therapeutic potential of a combined approach using HiCM-188 cardiomyocyte injection delivered intramyocardially alongside either LVAD implantation or CABG surgery in patients with advanced ischemic heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | low dose CABG+iPSC-CMs | CABG+0.5×10\^8 iPSC-CMs |
| BIOLOGICAL | High dose CABG/LVAD+iPSC-CMs | CABG+1.5×10\^8 iPSC-CMs or LVAD+1.5×10\^8 iPSC-CMs |
| OTHER | CABG/LVAD+Saline | CABG/LVAD+Saline |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-03-10
- Last updated
- 2025-03-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06866600. Inclusion in this directory is not an endorsement.